Drug Sales Trends for XARTEMIS XR
Annual Sales Revenues and Units Sold for XARTEMIS XR
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| XARTEMIS XR | ⤷ Start Trial | ⤷ Start Trial | 2022 |
| XARTEMIS XR | ⤷ Start Trial | ⤷ Start Trial | 2021 |
| XARTEMIS XR | ⤷ Start Trial | ⤷ Start Trial | 2020 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
Xartemis XR Market Analysis, Sales Forecast, Patent Status, and Generic Risk
Xartemis XR has limited commercial value as a U.S. branded product. The drug is an extended-release combination of oxycodone hydrochloride and acetaminophen, approved by the FDA in 2014 under NDA 202880. Its market faced strong substitution from low-cost immediate-release oxycodone/acetaminophen generics, payer restrictions on opioid products, and a small target population for twice-daily combination therapy. Public information does not establish a current active commercial franchise or meaningful recurring sales base.
The appropriate base-case forecast is near-zero U.S. revenue unless the product is relaunched, relicensed, or repositioned for a defined specialty-pain segment.
What is Xartemis XR and how does it work?
Xartemis XR is an oral extended-release tablet containing 7.5 mg of oxycodone hydrochloride and 325 mg of acetaminophen per tablet. The product was approved for the management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate.[1]
The product differs from standard Percocet-type products primarily through its extended-release dosing design. FDA labeling specifies dosing every 12 hours, with a maximum recommended dose of four tablets per day because of the cumulative acetaminophen exposure.[1]
| Product characteristic | Xartemis XR |
|---|---|
| Active ingredients | Oxycodone hydrochloride and acetaminophen |
| Strength | 7.5 mg oxycodone / 325 mg acetaminophen |
| Dosage form | Extended-release tablet |
| FDA application | NDA 202880 |
| FDA approval | 2014 |
| Controlled substance | Schedule II |
| Primary use | Acute pain requiring opioid treatment |
| Original commercial sponsor | Mallinckrodt |
| U.S. biologic status | Not applicable |
The combination creates a commercial limitation. Extended-release oxycodone is generally associated with chronic pain management, while acetaminophen combination products are commonly used for short-duration acute pain. Xartemis XR therefore occupies a narrow position between immediate-release postoperative products and longer-acting opioid monotherapies.
What is the FDA regulatory status of Xartemis XR?
Xartemis XR was approved through the FDA’s conventional new-drug application pathway. It is not a biologic, biosimilar, or 505(b)(2) follow-on product. Its regulatory status is governed by the NDA, opioid labeling requirements, acetaminophen safety limits, and federal controlled-substance rules.
The product’s major regulatory constraints are:
- Schedule II controls under the Controlled Substances Act.
- Opioid Medication Guide and risk-mitigation requirements.
- FDA labeling limits related to respiratory depression, misuse, abuse, addiction, and overdose.
- A maximum daily acetaminophen exposure of 1,300 mg under the labeled four-tablet regimen.
- Prescriber and payer scrutiny of extended-release opioid therapy.
- State-level opioid prescribing limits and prior authorization requirements.
The FDA’s opioid analgesic Risk Evaluation and Mitigation Strategy applies to extended-release and long-acting opioid products. Xartemis XR also carries the class-wide boxed warning associated with opioid use, including addiction, abuse, misuse, life-threatening respiratory depression, and neonatal opioid withdrawal syndrome.[2]
What is the Orange Book status of Xartemis XR?
The Orange Book is the controlling source for current reference-listed-drug and patent-listing status. Xartemis XR’s commercial and regulatory value depends on whether NDA 202880 remains active, whether the product is listed as marketed, and whether any patents remain listed against the drug.
No reliable investment case should assume meaningful Orange Book exclusivity without confirming a current FDA listing. The practical issue is not only whether an Xartemis XR patent has an unexpired term. A patent must also be listed against the relevant NDA and remain commercially relevant to a product that has active distribution.
| Exclusivity category | Commercial assessment |
|---|---|
| New chemical entity exclusivity | Expired |
| Orphan-drug exclusivity | Not applicable |
| Pediatric exclusivity | No material current protection identified |
| Regulatory exclusivity | No meaningful current exclusivity identified |
| Orange Book patent barrier | Requires current FDA verification |
| Current branded market protection | Weak or absent on public evidence |
The product’s initial five-year new chemical entity exclusivity would have expired in 2019, assuming the standard period applied from FDA approval. Any later protection would have depended on listed formulation, method-of-use, or other non-NCE patents.
What patents protect Xartemis XR?
The strongest potential intellectual-property claims for Xartemis XR would have involved the extended-release formulation, tablet design, dosing regimen, or manufacturing process rather than the active ingredients themselves.
Oxycodone, acetaminophen, and their immediate-release combination products have long commercial histories. Core composition-of-matter protection for the ingredients is therefore not available as a meaningful barrier. Any defensible patent position would need to rest on narrower claims covering:
- Controlled release of oxycodone from a combination tablet.
- Coformulation of oxycodone and acetaminophen.
- Release kinetics over a 12-hour dosing interval.
- Tablet manufacture and excipient selection.
- Specific methods of treating acute pain.
A patent estate for a combination opioid product is weaker than a composition-of-matter estate for a novel small molecule. Design-around risk is high because a generic manufacturer can pursue a different release matrix, use a different excipient system, or challenge the scope and validity of formulation claims.
No current projection should assign material terminal value to Xartemis XR based only on historic patent filings. The relevant questions are whether a patent remains unexpired, whether it is listed in the Orange Book, whether the listed claims cover an approved product, and whether a generic applicant has filed a Paragraph IV certification.
When does Xartemis XR lose exclusivity?
The practical exclusivity loss occurred after the expiration of the product’s five-year NCE period, no later than 2019 under the standard statutory framework. The economic loss occurred earlier because the product competed with established generic oxycodone/acetaminophen products that had much lower acquisition costs and broad prescriber familiarity.
| Milestone | Timing | Market effect |
|---|---|---|
| FDA approval | 2014 | Commercial launch eligibility |
| NCE exclusivity period | Approximately 2014-2019 | Limited regulatory protection |
| Post-exclusivity period | From approximately 2019 | Increased generic and payer exposure |
| Current commercial outlook | 2025 onward | Near-zero absent relaunch |
The product did not have the characteristics of a durable protected franchise. It lacked a novel active ingredient, had a narrow dosing proposition, and operated in a class subject to increasing restrictions.
Which companies are challenging Xartemis XR?
Publicly visible competitive pressure has primarily come from generic oxycodone/acetaminophen manufacturers rather than from a single high-profile branded challenger. Likely competitive products include generic immediate-release oxycodone/acetaminophen supplied by companies such as Teva, Amneal, Endo, Hikma, Rhodes, and other FDA-approved generic manufacturers, subject to product-specific market availability.
The principal competitive threat is substitution, not necessarily a direct generic copy of the extended-release tablet. Prescribers can use:
- Generic immediate-release oxycodone/acetaminophen.
- Oxycodone extended-release monotherapy.
- Hydrocodone/acetaminophen products.
- Non-opioid analgesics.
- Multimodal postoperative pain regimens.
The absence of a direct extended-release generic does not preserve a large market. Therapeutic substitution can remove most of the commercial opportunity.
What is the market size for Xartemis XR?
The addressable market is a small subset of the U.S. opioid analgesic market. Patients must require an opioid, need extended-release dosing, and be appropriate for a product that combines oxycodone with acetaminophen. That population is narrower than the broader market for oxycodone/acetaminophen.
The commercial market is constrained by five factors:
- Generic alternatives are substantially cheaper.
- Many payers prefer immediate-release products or require prior authorization.
- FDA and state policies discourage unnecessary extended-release opioid use for acute pain.
- Acetaminophen limits restrict dose escalation.
- Hospitals and surgical centers increasingly use multimodal pain protocols.
The product’s historical revenue is not consistently disclosed as a standalone line item in public company filings. That prevents a reliable calculation of peak sales, prescription volume, or current market share from SEC filings alone.
What are the Xartemis XR sales projections?
The following forecast is an analyst scenario, not company guidance. It assumes no relaunch, no new licensee, no successful premium reimbursement strategy, and no material shift in opioid prescribing policy.
| U.S. net sales scenario | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Base case | $0.3 million | $0.2 million | $0.1 million | $0.1 million |
| Low case | $0 | $0 | $0 | $0 |
| Relaunch case | $2 million | $4 million | $6 million | $7 million |
The base case represents residual prescriptions, institutional inventory, limited specialty distribution, or small-volume access through a relaunch arrangement. It does not assume an active national commercial campaign.
A relaunch case would require a new commercial strategy. The product would need a differentiated indication, competitive pricing, broad payer coverage, and evidence that twice-daily combination dosing improves adherence or reduces total treatment cost. Without those changes, a relaunch would face rapid substitution.
What generic entry risks exist for Xartemis XR?
Generic entry risk is high, but the larger commercial risk is therapeutic substitution. A direct generic applicant could challenge listed formulation or method patents through an ANDA and Paragraph IV certification. The patent holder could then bring Hatch-Waxman litigation, potentially triggering a 30-month stay under applicable conditions.[3]
Potential generic launch scenarios include:
| Scenario | Timing | Commercial consequence |
|---|---|---|
| Direct generic approved without litigation | Earliest post-exclusivity availability | Rapid price erosion |
| Paragraph IV litigation | Delayed launch | Limited value if the branded market is already small |
| Formulation design-around | Variable | Weakens enforcement leverage |
| No direct generic | No major protection | Prescriber substitution still erodes demand |
| Branded relaunch | Immediate commercial decision | Requires payer and prescriber repositioning |
For a low-revenue product, litigation economics are unfavorable. A patent holder may spend more defending a narrow formulation estate than the protected revenue justifies.
What patent litigation and settlement agreements affect Xartemis XR?
No major publicly established settlement framework is central to the current Xartemis XR commercial forecast. The key litigation risk would arise from an ANDA filer alleging invalidity, unenforceability, or non-infringement of any listed formulation or method-of-use patents.
A settlement could provide a licensed generic launch date, but its value would depend on remaining branded demand. For Xartemis XR, a settlement would likely have limited economic significance unless it preserved a profitable branded niche or delayed entry into a materially larger market than public information currently supports.
How does Xartemis XR compare with Percocet and other opioid products?
| Product | Release profile | Main commercial advantage | Main weakness |
|---|---|---|---|
| Xartemis XR | Extended release | Twice-daily combination dosing | Narrow use case and acetaminophen ceiling |
| Generic oxycodone/acetaminophen | Immediate release | Low cost and broad familiarity | More frequent dosing |
| Percocet brand | Immediate release | Brand recognition | Generic substitution |
| OxyContin and generic oxycodone ER | Extended release, oxycodone only | No acetaminophen ceiling | Higher opioid exposure and regulatory scrutiny |
| Hydrocodone/acetaminophen | Immediate release | Established acute-pain use | Generic competition and opioid restrictions |
Xartemis XR’s differentiation is insufficient to overcome the price and formulary advantages of generic immediate-release products.
What is the geographic coverage and manufacturing risk?
The commercial opportunity is overwhelmingly U.S.-focused. Xartemis XR’s name, FDA approval, and known regulatory history do not establish a broad international franchise. Expansion would require country-specific opioid approvals, controlled-substance registrations, labeling, pharmacovigilance, and distribution controls.
Manufacturing barriers are moderate. The product requires controlled-release tablet manufacturing and compliance with opioid production controls, but neither active ingredient is technically novel. Contract manufacturers or generic manufacturers with controlled-substance capabilities could reproduce the dosage form if regulatory and patent barriers were cleared.
Manufacturing risk is more likely to arise from supply-chain controls, quota allocation, opioid distribution compliance, and quality requirements than from irreplaceable process know-how.
How strong is the Xartemis XR patent estate?
The patent estate is commercially weak to moderate at best. Its potential strengths are formulation specificity and controlled-release design. Its weaknesses are the absence of active-ingredient novelty, high design-around potential, mature generic competition, and the limited value of defending a small branded market.
| Patent-strength factor | Assessment |
|---|---|
| Active ingredient novelty | Weak |
| Formulation differentiation | Moderate |
| Generic design-around risk | High |
| Regulatory exclusivity | Expired |
| Commercial durability | Weak |
| Litigation leverage | Limited |
| Manufacturing know-how | Moderate but not unique |
Key Takeaways
- Xartemis XR is an extended-release oxycodone/acetaminophen tablet approved by the FDA in 2014.
- Its NCE exclusivity expired approximately in 2019 under the standard five-year framework.
- The product competes against inexpensive generic oxycodone/acetaminophen and multiple therapeutic substitutes.
- Public disclosures do not support a meaningful current recurring sales base.
- Base-case U.S. sales are projected at less than $1 million annually from 2025 through 2028 without a relaunch.
- A direct generic challenge could erode remaining demand, but therapeutic substitution is the larger risk.
- The patent estate is formulation-dependent and vulnerable to design-around strategies.
- Biosimilar risk is not applicable because Xartemis XR is a small-molecule drug.
- A commercial relaunch would require new payer positioning, pricing, and evidence of value from extended-release combination dosing.
FAQs
Is Xartemis XR still commercially available?
Public information does not establish a meaningful active national commercial presence. Any remaining availability would likely be limited to residual inventory, specialty distribution, or a relaunch arrangement.
Is Xartemis XR an abuse-deterrent opioid?
The standard Xartemis XR labeling does not establish the product as an FDA-designated abuse-deterrent opioid. Extended release alone does not confer abuse-deterrent status.
Does Xartemis XR have a generic equivalent?
A direct generic equivalent would require FDA approval for the same extended-release oxycodone/acetaminophen dosage form. Even without a direct equivalent, immediate-release generic oxycodone/acetaminophen creates substantial therapeutic substitution risk.
Can Xartemis XR generate licensing revenue?
Licensing revenue would likely be modest unless a partner obtains a differentiated indication, secures favorable reimbursement, and reactivates commercial distribution. A patent license alone would not create substantial value in a small declining opioid market.
What would make Xartemis XR commercially attractive again?
The strongest potential catalysts would be a validated adherence benefit, a new clinical use with regulatory support, improved payer coverage, a lower-cost manufacturing arrangement, or a licensed relaunch focused on a narrow specialty-pain population.
References
- U.S. Food and Drug Administration. (2014). Xartemis XR prescribing information. NDA 202880.
- U.S. Food and Drug Administration. (2023). Opioid analgesic REMS.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Mallinckrodt plc. (2014-2020). Annual reports and Form 10-K filings.
- Drug Enforcement Administration. (2024). Controlled substances act and drug scheduling information.
More… ↓
